2024
Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer
Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M, Li A, Pichert M, Salazar M, Prsic E, Boffa D. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Medicine 2024, 13: e7028. PMID: 38711364, PMCID: PMC11074703, DOI: 10.1002/cam4.7028.Peer-Reviewed Original ResearchConceptsOptimal quality of careQuality of carePatient socioeconomic statusAssociated with improved qualityAssociated with improved quality of lifeEnd-of-lifeUS cancer populationPalliative treatmentQuality of lifeCox proportional hazards modelsMultivariate logistic regressionInformed decision makingProportional hazards modelFacility characteristicsNon-HispanicAssociated with lower ratesInsurance payer statusImproving informed decision makingCancer populationSocioeconomic statusHispanic ethnicityTreatment usePayer statusBlack raceLogistic regression
2023
Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy
Li A, Canavan M, Ermer T, Maduka R, Zhan P, Pichert M, Boffa D, Blasberg J. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. The Annals Of Thoracic Surgery 2023, 117: 163-171. PMID: 37774762, DOI: 10.1016/j.athoracsur.2023.09.023.Peer-Reviewed Original ResearchConceptsLower bilobectomyLeft pneumonectomyLung cancerMiddle lobeRight-sided lung cancerCox proportional hazards modelThirty-day morbidityTotal lung functionPreoperative risk stratificationThoracic Surgeons databaseProportional hazards modelPneumonectomy patientsUpper bilobectomyBronchial involvementPerioperative mortalityPerioperative riskPerioperative variablesPatient demographicsPulmonary resectionRight pneumonectomySecondary outcomesLung functionMiddle lobectomyPrimary outcomePropensity matching
2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy use
2021
Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis
Li AX, Resio BJ, Canavan ME, Papageorge M, Boffa DJ, Blasberg JD. Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis. Journal Of Thoracic Disease 2021, 0: 0-0. PMID: 34277037, PMCID: PMC8264694, DOI: 10.21037/jtd-21-1.Peer-Reviewed Original ResearchPrimary lung sarcomaNational Cancer DatabaseLung sarcomaOverall survivalSurgical resectionMultivariable Cox proportional hazards modelsNon-small cell lung cancer patientsNational Cancer Database AnalysisCell lung cancer patientsCox proportional hazards modelCharlson-Deyo scoreFive-year OSMultivariable Cox modelPositive lymph nodesMajority of patientsLung cancer patientsHigh tumor gradeHigh-grade tumorsDifferent histologic subtypesProportional hazards modelAdjuvant chemotherapyParenchymal resectionPulmonary malignancyWorse survivalAdjusted mortality
2019
Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustment
2017
The impact of tumor size on survival in T3 non-small cell lung-cancer with direct extension.
Kim C, Salazar M, Hoag J, Rosen J, Arnold B, Boffa D, Blasberg J. The impact of tumor size on survival in T3 non-small cell lung-cancer with direct extension. Journal Of Clinical Oncology 2017, 35: e20033-e20033. DOI: 10.1200/jco.2017.35.15_suppl.e20033.Peer-Reviewed Original ResearchTumor sizeAdjuvant chemoradiationAdjuvant chemotherapyAdjuvant therapyOverall cohortInferior survivalCurrent staging guidelinesNational Cancer DatabaseImportant prognostic variablesSubset of patientsPathologic N stageLarger tumor sizeNon-small cellProportional hazards modelN0 patientsN2 patientsNeoadjuvant therapyNodal diseaseImproved survivalPositive marginsStaging guidelinesCancer DatabaseN stagePrognostic variablesHazards model
2016
Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumors